Systemic surveillance for uveal melanoma: Approach to optimization
PLOS One · 19.08.2026 · 21 (8) · e0355405
DOI: 10.1371/journal.pone.0355405 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 19.08.2026. Verfasst von Emily C Zabor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research to Prevent Blindness.
Abstract (Originalsprache)
Importance There is lack of evidence assessing surveillance protocols to detect metastasis in patients with uveal melanoma (UM).
Objective
To explore hypothetical surveillance schedules anchored in the real-world data of our patient cohort with known prognostication status wherein, surveillance intervals ranging from every 1-month to every 12-months were statistically analysed.
Design
Retrospective, cohort study.
Setting
Single center.
Participants
Patients clinically diagnosed with UM and managed with standard of care local therapy who underwent prognostication by commercially available Gene Expression Profile (GEP) (Castle Biosciences, Friendswood, Texas, USA). Those classified as having low risk (Class 1) were offered a standard protocol (SP; hepatic ultrasonography (US) at 6-month intervals) while those with high risk (Class 2) were recommended to undergo enhanced protocol (EP) that incorporated either higher frequency (US every 3 months) or enhanced modality (EM, hepatic computed tomography/magnetic resonance imaging). Main outcome Measures Optimal scan interval.
Results
349 patients with median age of 62 years and 54% were male. Most patients were Class 1 (65%) and had choroidal location (75%). Median follow-up among survivors was 30.9 months (IQR: 19–57.9). 67 patients developed metastasis. The 5-year overall survival (OS) was 80% and the 5-year metastasis-free survival (MFS) was 71%. For Class 1 patients, 12-month scan interval was optimal as it had the minimal Euclidean distance to the point (0, 0) with a median of 2.92 months from negative to positive scan with an average of 2.83 scans per patient. For Class 2 patients, a 9-month scan interval was optimal as it minimized the Euclidean distance to the point (0, 0) with an average of 3.09 scans per patients and a median of 2.93 months from negative to positive scans. There was an association between the longer scan interval and size of metastatic lesion (>=6 months versus
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States of America.
- Department of Ophthalmology, University of Health Sciences, Gülhane Medical Faculty, Ankara, Turkey.
- Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland, Ohio, United States of America.
ORCID-Profile: Yağmur Seda Yeşiltaş, Arun D Singh
Förderung
- Research to Prevent Blindness
Zitieren
APA
Zabor, E. C., Yeşiltaş, Y. S., & Singh, A. D. (2026). Systemic surveillance for uveal melanoma: Approach to optimization. PLOS One, 21(8), e0355405. https://doi.org/10.1371/journal.pone.0355405
Vancouver
Zabor EC, Yeşiltaş YS, Singh AD. Systemic surveillance for uveal melanoma: Approach to optimization. PLOS One. 2026;21(8):e0355405. doi:10.1371/journal.pone.0355405
BibTeX
@article{Zabor2026,
author = {Zabor, Emily C and Yeşiltaş, Yağmur Seda and Singh, Arun D},
title = {Systemic surveillance for uveal melanoma: Approach to optimization},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0355405},
doi = {10.1371/journal.pone.0355405}
}
EUVIMED